Gilead acquiring Nimbus' NASH subsidiary

Gilead Sciences Inc. (NASDAQ:GILD) is acquiring the Nimbus Apollo Inc. subsidiary of Nimbus Therapeutics LLC (Cambridge, Mass.) for $400 million up front and up to $800 million in

Read the full 284 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE